Cargando…

The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer

BACKGROUND: Chemotherapy and surgery have been the mainstays of epithelial ovarian cancer (EOC) treatment so far. Cellular immunotherapies such as CAR T cell therapy have recently given hope of a cure for solid tumors like EOC. However, extrinsic factors associated with the CAR T cell manufacturing...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbari, Behnia, Soltantoyeh, Tahereh, Shahosseini, Zahra, Yarandi, Fariba, Hadjati, Jamshid, Mirzaei, Hamid Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225096/
https://www.ncbi.nlm.nih.gov/pubmed/37244991
http://dx.doi.org/10.1186/s12935-023-02948-0
_version_ 1785050326005448704
author Akbari, Behnia
Soltantoyeh, Tahereh
Shahosseini, Zahra
Yarandi, Fariba
Hadjati, Jamshid
Mirzaei, Hamid Reza
author_facet Akbari, Behnia
Soltantoyeh, Tahereh
Shahosseini, Zahra
Yarandi, Fariba
Hadjati, Jamshid
Mirzaei, Hamid Reza
author_sort Akbari, Behnia
collection PubMed
description BACKGROUND: Chemotherapy and surgery have been the mainstays of epithelial ovarian cancer (EOC) treatment so far. Cellular immunotherapies such as CAR T cell therapy have recently given hope of a cure for solid tumors like EOC. However, extrinsic factors associated with the CAR T cell manufacturing process and/or intrinsic dysregulation of patient-derived T cells, which could be associated with cancer itself, cancer stage, and treatment regimen, may hamper the efficacy of CAR T cell therapy and promote their exhaustion or dysfunction. METHODS: To investigate the association of these factors with CAR T cell exhaustion, the frequency of T and CAR T cells expressing three immune inhibitory receptors (i.e., TIM3, PD1, A2aR) generated from T cells of EOC patients and healthy controls was measured during each stage of CAR T cell production. RESULTS: Our findings revealed that primary T cells from EOC patients show significantly elevated expression of immune inhibitory receptors, and this increase was more prominent in patients undergoing chemotherapy and those with advanced cancer. In addition, the CAR T cell manufacturing process itself was found to upregulate the expression of these inhibitory receptors and more importantly increase the population of exhausted mesoCAR T cells. CONCLUSIONS: Our observations suggest that intrinsic characteristics of patient-derived T cells and extrinsic factors in CAR T cell production protocols should be considered and properly counteracted during CAR T cell manufacturing process. In addition, mitigating the signaling of immune inhibitory receptors through pharmacological/genetic perturbation during CAR T cell manufacturing might profoundly improve CAR T cells function and their antitumor activity in EOC and other solid tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02948-0.
format Online
Article
Text
id pubmed-10225096
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102250962023-05-29 The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer Akbari, Behnia Soltantoyeh, Tahereh Shahosseini, Zahra Yarandi, Fariba Hadjati, Jamshid Mirzaei, Hamid Reza Cancer Cell Int Research BACKGROUND: Chemotherapy and surgery have been the mainstays of epithelial ovarian cancer (EOC) treatment so far. Cellular immunotherapies such as CAR T cell therapy have recently given hope of a cure for solid tumors like EOC. However, extrinsic factors associated with the CAR T cell manufacturing process and/or intrinsic dysregulation of patient-derived T cells, which could be associated with cancer itself, cancer stage, and treatment regimen, may hamper the efficacy of CAR T cell therapy and promote their exhaustion or dysfunction. METHODS: To investigate the association of these factors with CAR T cell exhaustion, the frequency of T and CAR T cells expressing three immune inhibitory receptors (i.e., TIM3, PD1, A2aR) generated from T cells of EOC patients and healthy controls was measured during each stage of CAR T cell production. RESULTS: Our findings revealed that primary T cells from EOC patients show significantly elevated expression of immune inhibitory receptors, and this increase was more prominent in patients undergoing chemotherapy and those with advanced cancer. In addition, the CAR T cell manufacturing process itself was found to upregulate the expression of these inhibitory receptors and more importantly increase the population of exhausted mesoCAR T cells. CONCLUSIONS: Our observations suggest that intrinsic characteristics of patient-derived T cells and extrinsic factors in CAR T cell production protocols should be considered and properly counteracted during CAR T cell manufacturing process. In addition, mitigating the signaling of immune inhibitory receptors through pharmacological/genetic perturbation during CAR T cell manufacturing might profoundly improve CAR T cells function and their antitumor activity in EOC and other solid tumors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-023-02948-0. BioMed Central 2023-05-27 /pmc/articles/PMC10225096/ /pubmed/37244991 http://dx.doi.org/10.1186/s12935-023-02948-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Akbari, Behnia
Soltantoyeh, Tahereh
Shahosseini, Zahra
Yarandi, Fariba
Hadjati, Jamshid
Mirzaei, Hamid Reza
The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
title The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
title_full The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
title_fullStr The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
title_full_unstemmed The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
title_short The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer
title_sort inhibitory receptors pd1, tim3, and a2ar are highly expressed during mesocar t cell manufacturing in advanced human epithelial ovarian cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225096/
https://www.ncbi.nlm.nih.gov/pubmed/37244991
http://dx.doi.org/10.1186/s12935-023-02948-0
work_keys_str_mv AT akbaribehnia theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT soltantoyehtahereh theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT shahosseinizahra theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT yarandifariba theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT hadjatijamshid theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT mirzaeihamidreza theinhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT akbaribehnia inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT soltantoyehtahereh inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT shahosseinizahra inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT yarandifariba inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT hadjatijamshid inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer
AT mirzaeihamidreza inhibitoryreceptorspd1tim3anda2ararehighlyexpressedduringmesocartcellmanufacturinginadvancedhumanepithelialovariancancer